Literature DB >> 8132369

Antibiotic prophylaxis in recurrent erysipelas.

A C Sjöblom1, B Eriksson, C Jorup-Rönström, K Karkkonen, M Lindqvist.   

Abstract

Recurrences of erysipelas are especially prevalent in patients suffering from local impairment of circulation and intervention might thus be of benefit. Therefore a prospective, randomized, open study was undertaken to evaluate whether daily antibiotic prophylaxis would reduce the risk of recurrence. Patients with venous insufficiency or lymphatic congestion who had suffered two or more episodes of erysipelas during the previous 3 years and were admitted to the Infectious Disease Department at Roslagstull Hospital, Stockholm, Sweden, between November 1988 and November 1991 were included. Fourty patients, 20 on prophylaxis and 20 controls were followed according to a life table analysis during a median time of 15 months. Phenoxymethylpenicillin was prescribed as daily prophylaxis (while erythromycin was given to patients allergic to penicillin). Recurrences of erysipelas appeared to be reduced by daily antibiotic prophylaxis but the effect was not dramatic (p = 0.06). Only in patients with a high recurrence rate continuous antibiotic prophylaxis against erysipelas is indicated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8132369     DOI: 10.1007/bf01728920

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  [Erysipelas: epidemiological, clinical and therapeutic data (111 cases)].

Authors:  B Crickx; F Chevron; M Sigal-Nahum; S Bilet; F Faucher; C Picard; I Lazareth; S Belaich
Journal:  Ann Dermatol Venereol       Date:  1991       Impact factor: 0.777

2.  Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections.

Authors:  M Kremer; R Zuckerman; Z Avraham; R Raz
Journal:  J Infect       Date:  1991-01       Impact factor: 6.072

3.  Recurrent erysipelas: predisposing factors and costs of prophylaxis.

Authors:  C Jorup-Rönström; S Britton
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

4.  Epidemiological, bacteriological and complicating features of erysipelas.

Authors:  C Jorup-Rönström
Journal:  Scand J Infect Dis       Date:  1986

5.  Functional evaluation of chronic venous insufficiency by foot volumetry.

Authors:  L Norgren
Journal:  Acta Chir Scand Suppl       Date:  1974

6.  Prophylactic antibiotics in recurrent erysipelas.

Authors:  P Thind
Journal:  Lancet       Date:  1985-04-27       Impact factor: 79.321

7.  Prophylactic antibiotics in erysipelas.

Authors:  T Duvanel; Y Mérot; M Harms; J H Saurat
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

8.  [The importance of local factors in recurrent erysipelas].

Authors:  C Stöberl
Journal:  Z Hautkr       Date:  1985-05-01

9.  The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas.

Authors:  C Jorup-Rönström; S Britton; A Gavlevik; K Gunnarsson; A C Redman
Journal:  Infection       Date:  1984 Nov-Dec       Impact factor: 3.553

10.  Skin infections and acute nephritis in American Indian children.

Authors:  B F Anthony; L V Perlman; L W Wannamaker
Journal:  Pediatrics       Date:  1967-02       Impact factor: 7.124

View more
  16 in total

1.  Risk factors for erysipelas of the leg (cellulitis): case-control study.

Authors:  A Dupuy; H Benchikhi; J C Roujeau; P Bernard; L Vaillant; O Chosidow; B Sassolas; J C Guillaume; J J Grob; S Bastuji-Garin
Journal:  BMJ       Date:  1999-06-12

2.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

3.  A 60-year-old woman with recurrent cellulitis.

Authors:  Rohit Vijh; Rupal Shah; Nisha Andany
Journal:  CMAJ       Date:  2019-03-04       Impact factor: 8.262

4.  Low-dose penicillin for recurrent cellulitis?

Authors:  Liz Nguyen; Kate Rowland
Journal:  J Fam Pract       Date:  2014-01       Impact factor: 0.493

Review 5.  Antimicrobial prophylaxis in adults.

Authors:  Mark J Enzler; Elie Berbari; Douglas R Osmon
Journal:  Mayo Clin Proc       Date:  2011-07       Impact factor: 7.616

6.  Murine model of recurrent group G streptococcal cellulitis: no evidence of protective immunity.

Authors:  A L Bisno; J M Gaviria
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

7.  A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials.

Authors:  Stephanie C Chen; Scott Yh Kim
Journal:  Clin Trials       Date:  2016-06-30       Impact factor: 2.486

Review 8.  Cellulitis and erysipelas.

Authors:  Andrew D Morris
Journal:  BMJ Clin Evid       Date:  2008-01-02

9.  Cellulitis and erysipelas: prevention.

Authors:  Choon Chiat Oh
Journal:  BMJ Clin Evid       Date:  2015-11-18

10.  The risk factors of lower limb cellulitis: A case-control study in a tertiary centre.

Authors:  M N Norazirah; I S Khor; J Adawiyah; A M Tamil; M N Azmawati
Journal:  Malays Fam Physician       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.